doctor head
 
  pharmacy and drugs  
search Search
 
       About us       News      A-Z Drugs      Stores      Top Drugs      Contact  
  doctor doctor hand
 
  doctor legs  
 
 
 
 

  Diseases

  Newsletter
Subscribe to our newsletter:
Name:
E-mail:
    Search results
Search results for: candida

1 - 5 of 20 <<previous | next>>

Diseases results:

Mouth diseases
Std
Acromegaly
Endocarditis
Aids

Articles results:

Callisto Pharmaceuticals Announces Publication Of Research Articles On Atiprimod Preclinical Studies In Myeloid And Other Malignancies
Callisto Pharmaceuticals, Inc.


Adenosine Therapeutics, LLC Initiates Phase Ib Clinical Study With ATL146e
Adenosine Therapeutics, LLC, a leading adenosine drug discovery and development company, announced today it has initiated a two-part Phase Ib study in humans to evaluate apadenoson (ATL146e), a potent selective adenosine A2A agonist, as an anti-inflammatory agent.


Industry Affirms Support For Innovative Finance Mechanisms For Vaccines
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) welcomes the forthcoming presentation of the inaugural bond for the International Finance Facility for Immunization (IFFIm), to improve developing countries' access to under-used and new vaccines. IFFIm and innovative finance mechanisms such as Advance Market Commitments (AMCs)* reflect growing international recognition of the importance of disease prevention in general and vaccines in particular.


IFPMA Welcomes New WHO Director General
The International Federation of Pharmaceutical Manufacturers Associations (IFPMA) warmly welcomes the nomination by the World Health Organization Executive Board of Dr. Margaret Chan for the post of Director-General of the WHO. Subject to approval by the full WHO membership, Dr. Chan will succeed Dr. Jong Wook Lee, who died so tragically at the beginning of the 59th World Health Assembly in Geneva in May 2006.


Novartis Highlights Strong R&D Pipeline, Plans For Multiple New Product Launches And Novel Projects Moving Into Late-stage Trials
Novartis unveiled today new data on its promising pipeline amid plans for multiple new product approvals and launches over the next two years. Many of these anticipated approvals are for potentially best-in-class medicines that would advance treatment standards for patients with hypertension, diabetes, cancer and other diseases.




1 - 5 of 20 <<previous | next>>

© 2006-2010 pharmacy-and-drugs.com. All rights reserved.